| HOME >> BIOLOGY >> TECHNOLOGY |
AURORA, Ontario, Dec. 11 /PRNewswire-FirstCall/ -- Helix BioPharma Corp. (TSX, FSE: "HBP") today announced financial results for the first quarter of fiscal 2009, ended October 31, 2008.
RECENT HIGHLIGHTS
Results from Operations
Three month period ended October 31, 2008 compared to the same period in the previous year
Loss for the period
During the first quarter of fiscal 2009, the Company recorded a loss of $2,321,000 or $0.05 per common share, resulting in a higher loss of $677,000 when compared to the first quarter of fiscal 2008. The Company recorded a loss of $1,644,000, or $0.05 per common share in the first quarter of fiscal 2008.
Revenues
Revenues in the first quarter of fiscal 2009 totaled $1,119,000 (2008 - $885,000), resulting in an increase of $234,000 or 26.4% when compared to the first quarter of fiscal 2008.
Product Revenue
Product revenues totaled $921,000 in the first quarter of fiscal 2009 and represent 82.3% of total revenues. When compared to the first quarter of fiscal 2008, product revenues increased by $167,000 or 22.1% and are primarily driven by higher Orthovisc(R) product sales.
License Fees and Royalty Revenue
License fees and royalties totaled $198,000 in the first quarter of fiscal 2009 and represent 17.7% of revenues.
'/>"/>
| SOURCE Helix BioPharma Corp. Copyright©2008 PR Newswire. All rights reserved |